Table 2.
Effect of body weight on Grade ≥3 AEs, SAEs, and cardiac AEs in the Phase 3 HannaH study of SC vs IV trastuzumab.
| Grade ≥3 AE, n (%)a |
SAEs, n (%)a |
Cardiac AEs, n/N (%)b,c |
||||
|---|---|---|---|---|---|---|
| Body weight (kg) | SC (n = 297) | IV (n = 298) | SC (n = 297) | IV (n = 298) | SC (n = 297) | IV (n = 298) |
| <59 | 37 (52%) | 50 (65%) | 11 (15%) | 15 (19%) | 6/71 (8.5%) | 9/77 (11.7%) |
| ≥59 to <68 | 37 (53%) | 42 (50%) | 15 (21%) | 8 (10%) | 8/70 (11.4%) | 9/84 (10.7%) |
| ≥68 to <79 | 42 (59%) | 31 (44%) | 17 (24%) | 13 (19%) | 14/71 (19.7%) | 6/70 (8.6%) |
| ≥79 | 43 (51%) | 33 (49%) | 21 (25%) | 6 (9%) | 14/85 (16.5%) | 16/67 (23.9%) |